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Reward sensitivityAttention-deﬁcit/hyperactivity disorder (ADHD) is neurobehavioral disorder characterized by inattention,
hyperactivity/impulsivity and impaired reward system function, such as delay aversion and low reward sensitivity.
The pharmacological treatment for ADHD includes methylphenidate (MPH), or osmotic release oral system-MPH
(OROS-MPH), which increases extrasynaptic dopamine and noradrenaline levels by blocking their reuptake.
Although previous functional magnetic resonance imaging (fMRI) studies revealed that acute treatment with
MPH alters activation of the nucleus accumbens during delay aversion in children and adolescents with ADHD,
the effects a relatively long period of OROS-MPH treatment on delay aversion as well as reward sensitivity
remain unclear. Thus, we evaluated brain activation with fMRI during a reward sensitivity paradigm that consists
of high monetary reward and low monetary reward conditions before and after a 3-month treatment with
OROS-MPH in 17 children and adolescents with ADHD (mean age, 13.3 ± 2.2) and 17 age- and sex-matched
healthy controls (mean age, 13.0 ± 1.9).We found that before treatment therewas decreased activation of the nu-
cleus accumbens and thalamus in patients with ADHD during only the lowmonetary reward condition, whichwas
improved to same level as those of the healthy controls after the treatment. The observed change in brain activity
was associated with improved ADHD symptom scores, which were derived from Japanese versions of the ADHD
rating scale-IV. These results suggest that treatment with OROS-MPH for a relatively long period is effective in
controlling reward sensitivity in children and adolescents with ADHD.
© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-SA license.1. Introduction
Attention deﬁcit/hyperactivity disorder (ADHD) is an early onset
neurobehavioral disorder characterized by symptoms of inattention,
impulsivity, and/or hyperactivity (Biederman, 2005). Patients with
ADHD exhibit difﬁculties in several domains of attentional and cogni-
tive function: problem solving, planning, alertness, cognitive ﬂexibility,
sustained attention, response inhibition, and working memory (Angoldental Development, University
910-1193, Japan. Tel.: +81 776
.
nc. Open access under CC BY-NC-SA licet al., 1999; Biederman et al., 1991). Other domains involving affective
components, such as motivation and delay aversion for rewards, are
also affected (Biederman et al., 1993; Borland and Heckman, 1976;
Morrison, 1980). The worldwide prevalence of children with ADHD is
3 to 5% (Solanto, 2001). Prospective follow-up studies estimate that
about 50% of children with ADHD have symptoms that continue into
adulthood and, when left untreated, are associated with substance
abuse, depression, unemployment, and criminal offenses (Biederman
et al., 2006a; Molina et al., 2009).
ADHD has long been viewed as a neurobiological disorder of the
prefrontal cortex and its connections. Prefrontal cortex circuits relevant
to ADHD include the dorsal fronto-striatal, orbitofronto-striatal, and
fronto-cerebellar circuits (Durston et al., 2011). Functionally, the
fronto-cerebellar circuit has also been implicated in ADHD, in particular
in timing and building temporal expectations (Durston et al., 2007). The
dorsal fronto-striatal connections have been linked to cognitive control,ense.
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have been linked to reward and motivation (Alexander et al., 1986).
Studies using functional magnetic resonance imaging (fMRI) have
reported decreased activation of the ventral striatum, in both adoles-
cents and adults with ADHD, during reward anticipation (Plichta et al.,
2009; Scheres et al., 2007; Ströhle et al., 2008), reﬂecting the neural
processing associated with delay aversion for rewards in ADHD pa-
tients. However, a recent study demonstrated thatwhile striatal activity
during reward anticipation is not impaired in adolescents with ADHD, it
was impaired during reward outcome, suggesting abnormal striatal
sensitivity in ADHD (Paloyelis et al., 2012). Moreover, children with
ADHD require stronger rewards to modify their behavior and learn
faster when using direct reinforcement (Kollins et al., 1998), suggesting
that neural responses in ADHD patients are decreased during low
reward conditions. Therefore, ADHD patients may have decreased
reward sensitivity, thereby impeding responses to smaller rewards.
Conversely, increased reward sensitivity results in smaller rewards
eliciting the same responses as larger rewards. fMRI studies of the
neural substrates associated with reward sensitivity indicate that the
extent of striatal activation is associated with reward magnitude
(Izuma et al., 2008). While abnormal volume changes or atypical func-
tional changes in frontal or striatal regions have beenwell established in
ADHD children (Valera et al., 2007), little work has been conducted to
investigate the neural substrates associated with reward sensitivity in
the pediatric brain.
In the present study, we focused on the neural processing of reward
sensitivity in ADHD children and adolescents between the ages of 10–
16 years. There have been several studies using monetary gambling
tasks in pediatric populations, including studies of healthy children
(n = 19, mean age = 11.2) and adolescents (n = 17, mean age =
14.5) (Habib et al., 2012), ADHD patients (23 ADHD children vs. 20
healthy control children, age range = 7 to 12, mean ages of 9.6 and
9.1, respectively) (Luman et al., 2008), and early-onset schizophrenia
(15 adolescents with schizophrenia vs. 25 healthy control adolescents,
age range of 12 to 21) (Kester et al., 2006). Further, Habib et al.
(2012) provided evidence that the ability to experience counter-
factually mediated emotions, such as regret and relief, continues to
develop during late childhood and adolescence. The present study
stands in contrast to ﬁndings from other studies, in thatwe investigated
brain activation with fMRI during a reward sensitivity paradigm that
consists of high monetary reward (HMR) and low monetary reward
(LMR) conditions. Hence, we hypothesized that this approach would
be useful in revealing the dependence on reward magnitude of the
neural substrates associated with reward sensitivity in children as
well as in young adults (Izuma et al., 2008).
As the dopamine transporter is the main target for ADHD stimulant
medication, molecular imaging studies, using single photon emission
computed tomography and positron emission tomography (PET),
initially focused on the role of this marker, leading to the ﬁnding
that ADHD patients have increased dopamine transporter density
(Spencer et al., 2005). Recent meta-analysis revealed that despite high
inter-study heterogeneity, striatal dopamine transporter density in
ADHD patients was signiﬁcantly elevated by 14%, on average, compared
to healthy controls (Fusar-Poli et al., 2012). Methylphenidate (MPH)
constitutes the main ﬁrst-line ADHD therapy (Wilens, 2008) and in-
creases extrasynaptic dopamine and noradrenaline levels by blocking
their reuptake (Zetterström et al., 1988). Therapeutic doses of MPH
were found to produce more than 50% dopamine transporter blockade
in healthy volunteers (Volkow et al., 1998), leading to increased striatal
extracellular dopamine levels (Volkow et al., 2001). In adult ADHD
patients, attenuated dopamine levels in the caudate were increased fol-
lowing an acute intravenous single dose MPH treatment (0.5 mg/kg)
(Volkow et al., 2007). Consistent with this result, acute oral MPH treat-
ment (0.3 mg/kg) of ADHD adolescents increases dopamine concentra-
tions in the ventral striatum, which is associated with reduced
symptom severity (Rosa-Neto et al., 2005). Functionally, many studiesrevealed improvements in neural responses during reward, attention,
response inhibition, and resting state processing following MPH treat-
ment in ADHD patients (for see review, Cortese et al., 2012; Paloyelis
et al., 2007).With respect to reward tasks, reduced activation of the stri-
atum in ADHD children and adolescents during reward processing was
improved by acute MPH treatment (Rubia et al., 2009). The wealth of
data supporting the short-term efﬁcacy and safety of stimulants, such
as MPH, in treating children and adolescents with ADHD (Fone and
Nutt, 2005) is contrasted by a dearth of data on the long-term effects
of MPH treatment on reward processing.
Research continues to suggest that osmotic release oral system-
methylphenidate (OROS-MPH) lessens ADHD symptoms throughout
the day and has greater adherence, thought to be attributable to the
convenience of once-daily dosing (Abikoff et al., 2009; Chou et al.,
2009; Kim et al., 2009). Japan had no approved pharmacological
treatments for ADHD until the recent approval of OROS-MPH in
2007. In addition to OROS-MPH, the noradrenaline transport inhibitor
atomoxetine was approved for use in Japan in 2009. Although it has
been reported that OROS-MPH treatment improves executive function
in children and adolescents with ADHD (Yang et al., 2011; Yildiz et al.,
2011), only two studies have shown effects of OROS-MPH on cognitive
functions in Japanese children and adolescents with ADHD (Monden
et al., 2012; Sawada et al., 2010). Therefore, we need to accumulate
adequate evidence of OROS-MPH treatment on cognitive function as
well as reward processing in order to characterize the safety and efﬁca-
cy of long-term treatments in children and adolescents with ADHD.
Studies of the effects of stimulant treatment have shown that acute
MPH treatment improved activity in fronto-striatal circuits and the
cerebellum during cognitive inhibition in ADHD (Epstein et al., 2007).
However, maximal clinical responses to MPH are not observed until
approximately 4 to 6 weeks of treatment (Biederman et al., 2006b;
Spencer et al., 2005). A few studies have focused on the effects of rela-
tively long periods of MPH treatment on cognitive function in ADHD.
Schulz et al. (2012) showed that MPH treatment for 6 to 8 weeks in
ADHD children normalized activities in response inhibition task-
related regions, such as the motor and cingulate cortices. Konrad et al.
(2007) reported that MPH treatment for 1 year in children with
ADHD improved activation of brain regions involved in an executive
attention task. Stoy et al. (2011) examined the effect of MPH treatment
during childhood on differences in brain activation during reward pro-
cessing using a monetary incentive delay task in adult ADHD. With
OROS-MPH, although treatment for 6 weeks has been found to increase
activity in brain regions related to attention (Bush et al., 2008), the
effect of relatively long treatment periods on neural processes for
reward has not been investigated yet. Here, we examined whether a
3-month OROS-MPH treatment is associated with stable changes in
neural activity related to reward sensitivity in ADHD children and
adolescents using a longitudinal evaluation encompassing the pre- to
post-treatment period, with a concurrent comparison to normally
developing children and adolescents.2. Patients and methods
2.1. Participants
We recruited only healthy males and males with ADHD, to simplify
and strengthen the analysis and because very few females were in
the ADHD cohort at the Kumamoto University Hospital. Male children
and adolescents with ADHD met the Diagnostic and Statistical Manual
of Mental Disorders DSM-IV Text Revision (DSM-IV-TR) criteria
(American Psychiatric Association, 2000). This narrow age range was
chosen in an effort to maximize the similarity of the participants
recruited who were able to provide independent informed assent,
while minimizing variations in brain morphometry related to develop-
ment or maturation. To exclude other psychiatric diagnoses, the
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administered by a licensed pediatric–psychiatric clinician.
The diagnosis of ADHDwas conﬁrmed in structured interviewswith
investigators using the ADHD behavior module of the Japanese Version
of the Schedule for Affective Disorders and Schizophrenia for
School-Aged Children-Present and Lifetime Versions (K-SADS-PL-J)
(Kaufman et al., 1997; Miyawaki et al., 2003). It was conﬁrmed that
K-SADS-PL-J scored well on Cohen's κ (ADHD = 1.00, disruptive
behavior disorder = 0.91, anxiety disorders = 0.76, tic disorders =
0.75) for inter-rater reliability by the simultaneous interview method
and had concurrent validity for ADHD, disruptive behavior disorder,
and anxiety disorders using various evaluation scales (Miyawaki et al.,
2003). As additional instruments for diagnoses and ADHD symptom
severity, we used the Japanese versions of the ADHD Rating Scale-IV
(ADHD-RS-IV-J) (Yamazaki, 2003), the Barratt impulsiveness scale
(BIS) (Someya et al., 2001), strengths and difﬁculties questionnaires
(SDQ) (Iizuka et al., 2010), a scale of intrinsic versus extrinsic motiva-
tion toward learning (IEML) (Sakurai and Takano, 1985), the effort–
reward imbalance for learning model questionnaire (LERI) (Fukuda
et al., 2010) and the Chalder fatigue scale (CFS) (Tanaka et al., 2008).
Exclusion criteria for participants with ADHD were premature birth
(gestation ≤ 36 weeks) and diagnosis of any bipolar, psychotic,
obsessive–compulsive, or tic disorder at any point in their lifetime.
Exclusion criteria for comparison participants were a diagnosis of any
current DSM-IV axis I disorder at any point in their lifetime.
Participants who had any history of substance abuse, recent sub-
stance use, head traumawith loss of consciousness, epilepsy, signiﬁcant
fetal exposure to alcohol or drugs, perinatal or neonatal complications,
neurological disorders, ormedical conditions that could adversely affect
growth and development were excluded. Additional exclusion criteria
for both healthy and ADHD children and adolescents were full scale
intelligence quotient (IQ) below 80, asmeasured by theWechsler Intel-
ligence Scale for Children — Third Edition (WISC-III) (Wechsler, 1991),
or left-handedness according to the Edinburgh handedness inventory
(Oldﬁeld, 1971).
Twenty ADHD patients, aged 10–16 years, participated in the fMRI
experiments, once before treatment (btADHD) and once after treat-
ment (atADHD)with OROS-MPH for 3 months. Three out of 20 patients
were not able to complete the ﬁrst or second experiments, due to
motion artifacts during the fMRI scans. Thus, we analyzed data from a
total of 17 male patients.
To obtain data from age-matched healthy controls (HC), 17 healthy
children and adolescents, aged 10–16 years, were recruited from the
community, with school students targeted. Seventeen healthy age-
matched male children and adolescents completed the experiments.
Members of the control group participated once in the fMRI experi-
ment. The physical and neuropsychological characteristics of the partic-
ipants are shown in Table 1. Age, body mass index, and IQ score were
well matched between the patient and control groups. The protocol
was approved by the Ethics Committee of the Graduate School of
Medical Sciences, Kumamoto University, and all participants and theirTable 1
Physical and psychological characteristics of the participants.
Healthy controls ADHD patients p Value
Sample number, n 17 17 –
Years of age 13.0 ± 1.9 13.3 ± 2.2 0.680
BMI, m/kg2 18.9 ± 2.3 20.4 ± 3.6 0.134
WISC-III
FIQ score 100.5 ± 4.6 96.8 ± 11.9 0.231
VIQ score 101.5 ± 5.6 95.4 ± 11.5 0.055
PIQ score 99.1 ± 5.9 98.1 ± 14.1 0.777
BMI, body mass index; WISC-III, Wechsler Intelligence Scale for Children-Third Edition;
FIQ, full scale intelligence quotient; VIQ, verbal IQ; PIQ, performance IQ.
Values are presented as mean ± SD. p Values were obtained using the Student's t-test.parents gave written informed consent for participation in the study
after the study procedures had been explained to them, according to
the Declaration of Helsinki.2.2. Treatment of OROS-MPH for ADHD
In Japan, the Ministry of Health, Labour and Welfare approved
OROS-MPH (Concerta®, Johnson & Johnson Co.) for treatment of
ADHD in 2007, while other types of MPH have not been approved yet.
Therefore, we investigated the effects of OROS-MPH in the present
study. The ADHD patients were administered 18 to 36 mg (average
dose, 26.5 ± 7.4 mg) OROS-MPH (0.5–1.2 mg/kg per day) for
3 months. We did not administer a placebo to either ADHD patients
or healthy children and adolescents. The treatment protocol was also
approved by the Ethics Committee of Kumamoto University.2.3. Experimental paradigms for functional imaging
The fMRI experimental design is shown in Fig. 1. In the monetary
reward condition, the participants performed a simple gambling task,
which was a block-design version of the task used in a previous study
(Izuma et al., 2008). They were encouraged to try to earn as much
money as possible and were told that one session would be randomly
chosen at the end of the experiment and that their earnings in that
session would be given to them. In each trial (3 s), the participants
were presented with three cards labeled as “A”, “B” or “C” and were
asked to choose one card within 2 s by pressing a button with the
right index, middle or ring ﬁnger, which spatially corresponded to
the location of the cards. Immediately after the button press, the chosen
card was highlighted with a thick white border, and the outcome was
displayed for 1 s. If the participants did not press any button within
the choice period (2 s), the card they had chosen in one previous trial
was automatically chosen, and its outcome was displayed.
When the letters on each card were written in red, the trial was a
“monetary reward trial” in which each card was randomly associated
with 0, 30, or 60 yen. Each condition consisted of eight trials (24 s).
However, unknown to the participants, the total reward that they
could earn in each condition was predetermined. In the HMR condition,
they earned an average of 330 yen each (range = 270–390 yen),which
was consistently higher than the expected value of the eight reward
trials (240 yen). In the LMR condition, the participants earned an aver-
age of 150 yen each (range = 90–210 yen), which was consistently
lower than the expected value. The participants knew that the expected
value of the eight reward trials was 240 yen. However, they were not
informed of the presence of the HMR and LMR conditions. They also
participated in a no monetary reward (NMR) condition, indicated by
blue letters, in which they chose one card, but the outcome presented
was always “× × ×”, indicating that there was no monetary reward.
The NMR condition, or a ﬁxation rest condition (24 s), was always
inserted between two reward conditions, so that the start and end of
the reward manipulations could be clearly deﬁned. For half of the
participants, the colors (red and blue) used for the monetary reward
and nomonetary reward trials were switched to control for differences
in activity related to visual processing of colors. All the participants
completed a practice task for 2 min before scanning to ensure that all
participants understood the task.We conﬁrmed that during the practice
task, all the participants choose one card within the choice period (2 s)
at 100% accuracy (moving average of 8 trials). During scanning, they
performed a total of four sessions for 6 min 24 s [4 trials (24 s per
trial) for each of the four conditions (HMR, LMR, NMR, and ﬁxation
rest)] within which the HMR and LMR conditions were ordered differ-
ently, and the order of these four sessions was counterbalanced across
participants. All participants were paid a ﬁxed amount for their partici-
pation at the end of the experiment.
Fig. 1. Time course of stimulus display sequences for the monetary reward trial (top) and the no monetary reward trial (bottom). In each monetary reward trial, participants were
asked to choose one card within 2 s, and the outcome of the chosen card (0, 30, or 60 yen) was shown for 1 s. Each block consisted of eight monetary rewards or no-monetary
reward trials (24 s). In each no-monetary reward trial, participants were similarly asked to choose one card, but the outcome was always “× × ×”, indicating no monetary reward.
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All images were obtained using a 3-Tesla MR scanner (TRIO A Tim;
Siemens, Erlangen, Germany) located at the Graduate School of Medical
Sciences, Kumamoto University. For functional imaging, a series of 528
volumes (132 volumes per session) were acquired using interleaved
T2-weighted, gradient echo, echo planar imaging (EPI) sequences. Each
volume consisted of 44 transaxial slices with a thickness of 3.0 mm
between slices, which included the entire cerebrum and cerebellum
[repetition time (TR), 3000 ms; echo time (TE), 30 ms; ﬂip angle (FA),
90°; ﬁeld of view (FOV), 192 mm; in-plane matrix size, 64 × 64 pixels,
voxel dimensions, 3.0 × 3.0 × 3.0 mm; slice gap, 0 mm]. Comfortable
foam padding was tightly placed around the participant's head to mini-
mize head movement. To acquire a ﬁne structural whole-brain image,
magnetization-prepared rapid-acquisition gradient-echo (MP-RAGE)
images were obtained [TR, 1900 ms; TE, 4.62 ms; ﬂip angle, 15°; FOV,
256 mm; one slab; number of slices per slab, 176; voxel dimensions,
1.0 × 1.0 × 1.0 mm].
The ﬁrst four volumes acquired in each MRI session were discarded
due to unsteadymagnetization, and the remaining128 volumes per ses-
sion were used for analyses. Data were analyzed using the Statistical
Parametric Mapping 5 package (The Wellcome Trust Centre for Neuro-
imaging, London, UK; http://www.ﬁl.ion.ucl.ac.uk/spm) implemented
inMATLAB 7.7.0 (Mathworks, Natick, MA).We realigned the EPI images
with the time series and created a mean image. High-resolution
whole-brain T1-weighted images were then co-registered with the
mean image. This structural imagewas then normalized to theMontréal
Neurological Institute (MNI) T1 image template (Evans et al., 1994),
with the same parameters applied to all EPI images. The EPI images
were spatially smoothed in three dimensions using an 8 mm full-
width half-maximum Gaussian kernel.Statistical analyses were performed at two levels. First, individual
task-related activation was evaluated. We used a simple gambling
task, which was a block-design version of the task used in a previous
study (Izuma et al., 2008). In each task condition (i.e. HMR, LMR and
NMR), the event onset was designated as the presentation of the ﬁrst
stimulus (choice period of three cards labeled as “A”, “B” or “C”, see
Fig. 1) of the ﬁrst trial in a block. In each trial (3 s), the participants
were presented with three cards and were asked to choose one card
within 2 s by pressing a button. After the button press, the chosen
card was highlighted with a thick white border, and the outcome was
displayed for 1 s. A block consisted of eight trials (8 trials × 3 s =
24 s) in each condition. Therefore, the duration of each event (=one
block) was 24 s. Each task condition was repeated 4 times in one
session. We modeled 3 regressors (HMR, LMR and NMR), which were
convolved with a canonical hemodynamic response function to obtain
the expected signal changes caused by the tasks. Regressors that were
of no interest, such as the six realignment parameters that account for
motion-related variance, were also included in the design model. The
data were high-pass ﬁltered with a cut-off period of 128 s to remove
low-frequency signal drifts. An autoregressivemodelwas used forwhit-
ening the residuals so as to meet the assumptions for application of a
general linear model (GLM). The effect of each condition was evaluated
with a GLM. The weighted sum of the parameters estimated in the indi-
vidual analyses consisted of “contrast” images. Speciﬁcally, for each par-
ticipant the following ﬁrst level contrast images were generated: (HMR
minus NMR) and (LMR minus NMR).
Second, the contrast images corresponding to each condition for
each participant were used for group analyses with a random-effects
model to obtain population inferences (Friston et al., 1999). We used
a ﬂexible factorial design that can compare the activities of reward
level contrasts within (HMR minus NMR) and (LMR minus NMR), and
Table 3
Performance of monetary reward tasks before and after OROS-MPH treatment in patients
with ADHD.
Healthy controls ADHD patients
Before After
RT of HMR, ms 593 ± 265 570 ± 214 573 ± 259
RT of LMR, ms 545 ± 243 520 ± 209 538 ± 299
RT of NMR, ms 544 ± 252 448 ± 97 488 ± 237
RT, reaction time; HMR, high monetary reward; LMR, low monetary reward; NMR, no
monetary reward. Values are presented as mean ± SD.
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well as compare those between the HC and btADHD or atADHD groups
by non-repeated measures. The resulting set of voxel values for each
comparison constituted a statistical parametric map of t statistics
[SPM(t)]. Signiﬁcant signal changes for each contrast were assessed by
means of t statistics on a voxel-by-voxel basis. The threshold for the
SPM(t) for group analyses was set at p b 0.005 at the voxel level and
p b 0.05 with a correction for multiple comparisons at the cluster
level for the entire brain (Izuma et al., 2008).
Comparisons of the HMR and LMR conditions with the NMR con-
dition (HMR or LMR minus NMR) were performed in order to obtain
the activation pattern of the two types of reward task processing
(Izuma et al., 2008) in each study group (HC, btADHD and atADHD).
To specify the brain areas involved in reward sensitivity, we used
the reward level contrast (HMR minus LMR) masked by the high
reward contrast (HMR minus NMR) in each study group. To specify
the brain areas involved in the treatment of OROS-MPH, we used
the study group contrast (atADHD minus btADHD or HC) without
masked images in the HMR and LMR conditions (HMR or LMR
minus NMR). Anatomic localization of signiﬁcant voxels within clus-
ters was performed using the Wake Forest University (WFU)
Pick-Atlas (Maldjian et al., 2003) and a probabilistic cytoarchitectonic
map (Eickhoff et al., 2005).
The effects of task condition (HMR, LMR and NMR) or study group
(HC, btADHD and atADHD) on the task performance (reaction time)
in each task condition were analyzed using a two-way analysis of var-
iance (ANOVA). A two-way repeated measures ANOVA was used to
investigate the effects of task and study group on reaction time be-
tween the btADHD and atADHD groups. When statistically signiﬁcant
effects were found, intergroup differences were evaluated using the
paired t-test or Student's t-test. All p values were two-tailed, and p
values less than 0.05 were considered signiﬁcant. These analyses
were performed with the IBM SPSS 19.0 software package (SPSS Inc,
Chicago, IL).
3. Results
3.1. Questionnaire results
The results for questionnaires are summarized in Table 2. The
inattention, hyperactivity/impulsivity and total scores in ADHD-RS-
IV-J, BIS, and QCD for the btADHD group were signiﬁcantly higher
than those of the HC. The IEML, LERI and CFS scores were similar
between the two groups. In the ADHD patients, inattention,
hyperactivity/impulsivity and total scores in ADHD-RS-IV-J, BIS, SDQ
and IEML after treatment were improved in comparison with those
before treatment. The LERI and CFS scores were not changed after
treatment. Although the inattention, hyperactivity/impulsivity and
total scores of ADHD-RS-IV-J and SDQ in the atADHD group wereTable 2
Effects of OROS-MPH treatment on questionnaire results in patients with ADHD.
Healthy controls
ADHD-RS-IV-J
Inattention score 4.2 ± 4.3
Hyperactivity/Impulsivity score 1.1 ± 1.3
Total score 5.3 ± 5.4
BIS score 70.4 ± 6.9
QCD score 49.0 ± 7.6
IEML score 84.2 ± 14.9
LERI score 0.90 ± 0.24
CFS score 10.4 ± 5.8
ADHD-RS-IV-J, Japanese versions of the ADHD rating scale-fourth edition; BIS, Barratt impul
versus extrinsic motivation toward learning; LERI, effort–reward imbalance for learning mode
⁎⁎p b 0.01, ⁎⁎⁎p b 0.001, signiﬁcantly different from the corresponding values for the healthy a
the corresponding values for ADHD patients before treatment with OROS-MPH (paired t-test).still higher than those of the HC group, BIS scores between the
atADHD and HC groups were not different.
3.2. Behavioral results
The results for reaction times are summarized in Table 3. In compar-
isons among the HC, btADHD and atADHD groups, two-way ANOVA re-
vealed no signiﬁcant main effects of task condition [F(2, 144) = 1.64,
p = 0.198], study group [F(2, 144) = 0.54, p = 0.587] or interactions
[F(2, 144) = 1.40, p = 0.967] on reaction time. In comparisons be-
tween the btADHD and atADHD groups, two-way repeated measures
ANOVA revealed a signiﬁcant main effect of task condition on reaction
time [F(1, 16) = 14.05, p = 0.002], whereas no signiﬁcant effects on
reaction time were observed with the study group [F(1, 16) = 0.22,
p = 0.647] or interactions [F(1, 16) = 0.76, p = 0.396]. These results
indicate that the reaction times among the HC, btADHD and atADHD
groups were not different.
3.3. Imaging results
Imaging results for the HMR and LMR conditions (HMR or LMR
minus NMR) are shown in Fig. 2 and Tables 4 (HC), 5 (btADHD) and
6 (atADHD). In the HMR condition, activation of the right middle
and medial frontal gyri, cingulate gyrus, inferior parietal lobule,
precuneus, bilateral striatum (including the nucleus accumbens),
thalamus and cerebellum was commonly observed in the HC group,
as well as in the btADHD and atADHD groups (Fig. 2A, Tables 4–6).
During the HMR condition, the right inferior frontal gyrus and insula
were commonly activated in the HC and atADHD groups, but not in
the btADHD group. The right middle frontal gyrus, cingulate gyrus,
insula, caudate and cerebellum were also commonly activated during
the LMR condition in the HC, btADHD and atADHD groups. Although
activation of the right medial frontal gyrus, bilateral nucleus
accumbens and thalamus during the LMR condition was observed in
the HC and atADHD groups, this was not observed in the btADHD
group (Fig. 2B, Tables 4–6).ADHD patients
Before After
16.8 ± 4.4⁎⁎⁎ 11.8 ± 6.3⁎⁎⁎,††
7.3 ± 6.1⁎⁎⁎ 3.5 ± 3.7⁎,†
24.1 ± 8.8⁎⁎⁎ 15.3 ± 8.3⁎⁎⁎,††
77.8 ± 9.8⁎ 65.7 ± 10.9†††
33.9 ± 10.1⁎⁎⁎ 39.4 ± 8.9⁎⁎,†
75.5 ± 17.2 83.2 ± 15.5†
1.05 ± 0.36 0.94 ± 0.25
13.4 ± 6.8 12.8 ± 5.9
siveness scale; QCD, questionnaires for children with difﬁculties; IEML, scale of intrinsic
l questionnaire; CFS, Chalder fatigue scale. Values are presented as mean ± SD. ⁎p b 0.05,
dolescents (Student's t-test). †p b 0.05, ††p b 0.01, †††p b 0.001, signiﬁcantly different from
BA
Fig. 2. Statistical parametric maps of (A) high monetary reward (HMR minus NMR) and (B) low monetary reward (LMR minus NMR) in healthy controls (HC) and ADHD patients
before (btADHD) and after treatment (atADHD) with OROS-MPH are shown. Right (R) and left (L) sides and y-axis (MNI coordinate) are indicated.
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we examined task contrast (HMR minus LMR) in each study group
(Fig. 3A). We found that although the activation level of each activated
region (see Table 4) was not different between the LMR and HMR con-
ditions in the HC group, activation of the bilateral nucleus accumbens
was lower in the LMR than in the HMR condition in the btADHD
group. In the atADHD group, differences in activation of the bilateral
nucleus accumbens between the LMR and HMR conditions were not
observed. No differences were found in each study group when the
LMR and HMR conditions (LMRminus HMR) were compared.
To specify the brain areas affected by OROS-MPH treatment, we
examined the study group contrast (atADHD minus btADHD or HC) in
the HMR (HMR minus NMR) and LMR (LMR minus NMR) conditions
(Fig. 3B). In the HMR condition, no differences were detected in the
activation level of each activated region (see Tables 5, 6) between the
atADHD and btADHD groups. However, in the LMR condition, thalamic
activation was higher in the atADHD group than in the btADHD group.
Thalamic activation during the LMR condition was also higher in the
HC group than in the btADHD group. The strongly activated thalamic
areas overlapped between the HC and atADHD groups. The activation
levels in other regions were similar in the HC and atADHD groups, in
both the HMR and LMR conditions. The results of the analysis of reward
sensitivity using task contrast (HMR minus LMR) in the btADHD group
(Fig. 3A) indicated that thalamic activation (x = −20, y = −18,
z = 6) in the LMR condition tended to be lower than in the HMR
condition (uncorrected p b 0.01, cluster size = 15 voxels).
We found that the ADHD-RS-IV-J, BIS, SDQ and IEML scores, as well
as decreased activation of the nucleus accumbens and thalamus during
the LMR condition before treatment, were improved after treatment in
the ADHDpatients. In order to clarify the effect of OROS-MPH treatment
on the relationship between improved ADHD symptoms and brain ac-
tivity during low reward processing, we performed correlation analyses
between questionnaire delta scores (atADHDminus btADHD) and delta
activation of the nucleus accumbens and thalamus (atADHD minus
btADHD) (Table 7). In accordance with circular analysis (Kriegeskorte
et al., 2009), we redeﬁned the regions of interest for the nucleus
accumbens and thalamus, based on a previous study that used the
same monetary reward tasks (Izuma et al., 2008). This study showed
activities, using the MNI-group coordinates, for the left (x = −14,
y = 10, z = −4) and right (x = 12, y = 10, z = −4) nucleusaccumbens, as well as the thalamus (x = −14, y = −14, z = 14), in
the (HMR minus NMR) condition. In the present study, activation of
the left and right nucleus accumbens and thalamus were summarized
with principal eigenvariates over all voxels within a radius of 4 mm,
with group coordinates determined using the volume-of-interest tool
in SPM5. The correlation analyses revealed that the delta activation of
the left nucleus accumbens was negatively correlated with the delta of
inattention score of ADHD-RS-IV-J. Likewise, a negative correlation
was observed between the thalamic activation delta and delta scores
for inattention of ADHD-RS-IV-J. Signiﬁcant correlations were not
observed between the activation deltas for the nucleus accumbens or
thalamus and the deltas of other questionnaire scores.
Although we investigated the effects of OROS-MPH dosage on acti-
vation of the nucleus accumbens and thalamus and questionnaire
scores, signiﬁcant differences were not observed among the dosage
groups (18 mg, 27 mg and 36 mg) (Table 8).
4. Discussion
Consistent with our results, a prior study showed that clinical
improvement, in terms of inattention and hyperactivity/impulsivity in
Japanese children and adolescents with ADHD lessened following
OROS-MPH treatment for 2–3 months (Sawada et al., 2010). Although
a few fMRI studies have shown the effects of relatively-long periods of
MPH treatment on cognitive function, such as the attention task for chil-
dren and adultswith ADHD (Konrad et al., 2007; Stoy et al., 2011), there
are no previous reports of the effects of OROS-MPH treatment on
monetary reward processing in children and adolescents with ADHD.
Thus, we are the ﬁrst to demonstrate the possible effect of OROS-MPH
treatment on the reward system in the brain of ADHD children and
adolescents.
Fronto-striatal dysfunction is one of the pathophysiological hall-
marks of ADHD (Cubillo et al., 2010). Previous fMRI studies on the
effects of a gambling task have shown decreased activation of the ven-
tral striatum in both adolescents and adults with ADHD during mone-
tary reward processing (Plichta et al., 2009; Scheres et al., 2007;
Ströhle et al., 2008). These studies evaluated brain activation during a
delay while waiting for a reward (reward anticipation). However, the
present study evaluated the neural substrates associated with reward
sensitivity during reward outcome, as opposed to reward anticipation.
Table 4
Activated brain regions associated with the high monetary reward (HMR) and low
monetary reward (LMR) conditions in healthy controls.
Brain region Healthy control
Cluster Side BA MNI coordinate Z value
Size p Value x y z
HMR minus NMR
Insula 11,477 b0.001 L −30 18 −2 6.44
R 32 22 0 6.89
Caudate L −10 6 0 5.64
R 12 8 4 5.18
Putamen L −22 10 12 4.25
R 20 10 8 3.97
Nucleus accumbens L −12 2 −2 6.08
R 14 8 −2 5.71
Thalamus L −8 −20 12 4.07
R 6 −16 14 5.29
Cerebellum L −8 −76 −28 4.47
R 6 −78 −22 3.92
Postcentral gyrus 3015 b0.001 R 40 52 −36 52 3.24
Inferior parietal lobule R 40 40 −52 38 6.28
Superior parietal lobule R 7 38 −64 54 5.32
Precuneus L 7 −6 −68 44 3.56
R 7 8 −66 44 5.65
Middle frontal gyrus 2152 b0.001 R 10 38 56 12 3.24
R 46 50 32 30 4.24
R 9 46 16 40 3.73
R 6 40 6 56 4.39
Inferior frontal gyrus R 9 46 8 26 4.54
Medial frontal gyrus 1641 0.001 R 9 6 34 36 5.43
Cingulate gyrus L 32 −8 16 48 5.11
R 32 6 22 44 4.86
LMR minus NMR
Inferior frontal gyrus 8493 b0.001 L 47 −30 20 −2 4.61
R 47 32 20 −2 5.56
Insula L −30 18 −4 5.15
R 30 22 2 5.45
Caudate L −10 6 0 3.94
R 14 10 6 4.54
Putamen L −20 4 16 3.98
R 16 12 0 4.67
Nucleus accumbens L −10 6 −2 4.21
R 12 4 −4 3.90
Thalamus L −12 −12 8 4.24
R 12 −10 10 4.73
Cerebellum 5259 b0.001 L −8 −74 −26 4.67
R 4 −76 −26 4.35
Medial frontal gyrus 1257 0.004 L 9 −8 28 34 3.18
R 9 6 34 36 4.74
Cingulate gyrus L 32 −10 16 48 4.30
R 32 6 22 44 4.26
Middle frontal gyrus 1014 0.013 R 46 46 36 22 3.60
R 9 50 28 36 3.81
R 6 40 8 54 3.43
NMR, no monetary reward; L, left; R, right; BA, Brodmann's area; MNI, Montréal
Neurological Institute. The extent threshold was set at p = 0.05 with a correction for
multiple comparisons at the cluster level for the entire brain. The height threshold
was set at p = 0.005 (uncorrected) at the voxel level.
Table 5
Activated brain regions associated with the high monetary reward (HMR) and low
monetary reward (LMR) conditions before treatment of ADHD patients.
Brain region ADHD (before treatment)
Cluster Side BA MNI coordinate Z value
Size p Value x y z
HMR minus NMR
Middle frontal gyrus 20,145 b0.001 R 9 50 28 36 4.66
R 6 30 6 44 4.78
Medial frontal gyrus L 6 −8 28 38 3.97
R 9 8 30 38 4.84
Cingulate gyrus R 32 8 24 46 5.24
Caudate L −10 6 0 5.43
R 12 8 0 6.01
Putamen L −20 10 12 3.89
R 22 10 10 4.17
Nucleus accumbens L −10 0 −8 3.51
R 10 0 −10 4.02
Thalamus L −24 −30 6 3.87
R 6 −20 14 3.84
Cerebellum L −4 −74 −22 5.48
R 34 −66 −28 3.91
Inferior parietal lobule 2532 b0.001 R 40 40 −46 42 4.07
Precuneus R 7 10 −62 46 5.15
Inferior parietal lobule 1200 0.006 L 40 −42 −40 40 3.25
Superior parietal lobule L 7 −28 −60 44 4.16
Precuneus L 7 −16 −62 50 3.61
LMR minus NMR
Inferior parietal lobule 4667 b0.001 L 40 −42 −42 42 3.44
R 40 44 −50 46 4.45
Superior parietal lobule L 7 −30 −56 40 4.29
R 7 38 −66 52 4.20
Precuneus R 7 10 −62 46 5.89
Cerebellum 2739 b0.001 L −28 −62 −32 4.65
R 28 −60 −28 3.67
Insula 1352 0.003 R 30 22 2 5.46
Middle frontal gyrus R 10 32 48 2 2.60
Caudate R 8 16 10 4.04
NMR, no monetary reward; L, left; R, right; BA, Brodmann's area; MNI, Montréal
Neurological Institute. The extent threshold was set at p = 0.05 with a correction for
multiple comparisons at the cluster level for the entire brain. The height threshold
was set at p = 0.005 (uncorrected) at the voxel level.
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ity of adolescents with ADHD during reward anticipation was not
altered in comparison to healthy adolescents, activity during a high
monetary reward condition (5 £ = around 680 Japanese yen) was
increased. In the present study, an increase in striatal activation during
the HMR condition [average of 330 yen each (range = 270–390 yen)]
in ADHD patients was not observed. In contrast to the HMR condition,
striatal activation was decreased during the LMR condition [average
of 150 yen each (range = 90–210 yen)]. These results suggest that
elevated or reduced striatal activity reﬂects impairment of striatal sen-
sitivity due to dysfunctional transfer of phasic dopamine release fromthe actual reward to its predicting stimulus, thereby resulting in im-
paired appraisal of motivational outcomes and subsequent behavioral
adaptation (Tripp and Wickens, 2008).
Although a number of studies have reported that activation of the
nucleus accumbens during monetary reward anticipation occurs
(Dreher et al., 2007; Ernst et al., 2004; Kirsch et al., 2003; Knutson
et al., 2001, 2005; Liu et al., 2007), a few studies have also reported an
association between activation of the nucleus accumbens and reward
outcome (Breiter et al., 2001; Izuma et al., 2008). Other brain regions
have been suggested to play a role in reward outcome, including the
orbitofrontal and medial prefrontal cortex (Dillon et al., 2008;
Knutson et al., 2003; O'Doherty et al., 2003), the cingulate cortex
(Knutson et al., 2003; Nieuwenhuis et al., 2005), the amygdala
(Dreher et al., 2007; Hamann et al., 2004; Stoeckel et al., 2008), and
the thalamus (Izuma et al., 2008; Rademacher et al., 2010; Thut et al.,
1997). The present unexpected ﬁnding of pronounced thalamic activa-
tion associated with monetary reward adds to the results of prior
imaging studies, which have shown recruitment of this structure during
the processing of monetary reward (Bjork et al., 2004; Izuma et al.,
2008; Martin-Soelch et al., 2003; Thut et al., 1997).
MPH treatment for ADHD patients increases extrasynaptic dopa-
mine and noradrenaline levels by blocking reuptake (Zetterström
et al., 1988). Acute oral MPH treatment of ADHD adolescents increases
dopamine concentrations in the ventral striatum, with the dopamine
Table 6
Activated brain regions associated with the high monetary reward (HMR) and low
monetary reward (LMR) conditions after treatment of ADHD patients.
Brain region ADHD (after treatment)
Cluster Side BA MNI coordinate Z value
Size p Value x y z
HMR minus NMR
Middle frontal gyrus 20,217 b0.001 R 10 40 56 −6 4.87
R 46 36 32 22 4.09
R 9 50 30 34 5.53
R 6 30 6 46 4.92
Medial frontal gyrus R 9 4 32 36 5.42
Inferior frontal gyrus R 9 46 6 28 3.74
Cingulate gyrus R 32 8 24 44 5.38
Insula R 30 22 0 6.83
Caudate L −10 8 2 5.18
R 12 10 2 5.67
Putamen L −18 10 10 3.11
R 20 12 10 2.99
Nucleus accumbens L −10 0 −4 3.75
R 10 4 −8 3.54
Thalamus L −12 −8 4 3.93
R 10 −4 4 5.08
Cerebellum L −28 −64 −30 5.69
R 6 −76 −16 4.79
Inferior parietal lobule 5233 b0.001 R 40 36 −58 44 5.47
Superior parietal lobule L 7 −30 −56 42 4.92
Precuneus L 7 −12 −66 46 3.93
R 7 8 −68 44 5.13
LMR minus NMR
Middle frontal gyrus 2905 b0.001 R 6 30 6 44 5.08
Medial frontal gyrus R 9 4 30 34 5.92
Cingulate gyrus R 32 6 24 42 5.81
Inferior parietal lobule 2760 b0.001 R 40 36 −60 44 5.31
Superior parietal lobule R 7 42 −46 36 5.31
Precuneus R 7 8 −66 44 5.18
Caudate 2376 b0.001 L −10 6 2 3.31
R 14 4 20 2.83
Nucleus accumbens L −10 4 −2 3.21
R 8 0 −2 3.21
Thalamus L −6 −8 0 3.73
R 8 −6 4 4.47
Cerebellum R 4 −30 −30 2.76
Inferior parietal lobule 979 0.015 L 40 −40 −46 42 3.45
Superior parietal lobule L 7 −28 −58 42 4.75
Precuneus L 7 −12 −66 46 2.77
Insula 935 0.019 R 30 22 2 6.51
NMR, nomonetary reward; L, left; R, right; BA, Brodmann's area;MNI,MontréalNeurolog-
ical Institute. The extent thresholdwas set at p = 0.05with a correction formultiple com-
parisons at the cluster level for the entire brain. The height thresholdwas set at p = 0.005
(uncorrected) at voxel level.
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severity (Rosa-Neto et al., 2005). In contrast to acute MPH treatment
in children and adolescentswith ADHD, changes in dopaminergic trans-
mission in each brain region following long-term MPH treatment are
unclear. Although changes in thalamic dopamine concentrations
following MPH treatment were not described in this study (Rosa-Neto
et al., 2005), PET studies, using radiolabeled MPH, of healthy adults
have shown that the availability of the dopamine transporter in
the basal ganglia is the highest, and the second highest region is the
thalamus, relative to the temporal insula, cingulate, orbitofrontal,
frontal and occipital cortices (Wang et al., 1995). Therefore, MPH and
OROS-MPH should theoretically increase dopamine transmission with-
in the ventral striatum(including the nucleus accumbens) aswell as the
thalamus. It is possible that acute MPH treatment alters dopaminergic
transmission only in the ventral striatum (Rosa-Neto et al., 2005). How-
ever, both MPH and OROS-MPH treatments, for a relatively long period
in ADHD children and adolescents, may alter dopaminergic activity in
both the ventral striatum and thalamus; thus, the role played by theseregions in reward sensitivity processing may improve after treatment
for 3 months.
Improved activation of the nucleus accumbens and thalamus during
lower monetary reward processing were correlated with decreased
inattention score of ADHD-RS-IV-J following OROS-MPH treatment in
the present study. Previous ﬁndings have shown that cortico-striatal-
thalamic circuits are associated with reward, and task demands trigger
highly similar processes that have been linked to attentional control
(Gitelman et al., 1999; Hopﬁnger et al., 2000; Krebs et al., 2012). In
keeping with this notion, the reward mechanism appears to act by uti-
lizing andmodulating attentional processes that are typically employed
in endogenous attentional control, as has been suggested (e.g., Pessoa
and Engelmann, 2010). Thus, improvement of reward processing
following OROS-MPH treatmentmay contribute to the improved atten-
tional function involved in ADHD symptoms.
Although the effect of MPH treatment on ADHD children and adoles-
cents has been shown, a relationship between MPH treatment and the
risk for substance abuse in ADHD patients has also been discussed
(Robbins, 2002). Lambert and Hartsough (1998) showed that cocaine
abuse and nicotine abuse were associated with ADHD patients who had
used stimulant medication in childhood in contrast to un-medicated
ADHD patients. Conversely, ameta-analysis revealed a 1.9-fold reduction
in the risk for substance use disorders in children and adolescents who
were treated with stimulants, including MPH, compared with those
who did not receive pharmacotherapy (Wilens et al., 2003). OROS-MPH
has an immediate-release outer coating and a core that delivers MPH
based on osmotic pressure (Markowitz et al., 2003). This technology
combines the beneﬁts of immediate-release MPH formulations
(IR-MPH) with sustained drug release, where the time to maximum
concentrations (Tmax) is approximately 6 to 8 h (Modi et al., 2000). In
addition, the maximum plasma concentration (Cmax) for OROS-MPH is
lower than IR-MPH (Modi et al., 2000). OROS-MPH shows effectiveness
and side effects similar to those seen with IR-MPH (Weisler, 2007). In
comparison with IR-MPH, the pharmacokinetic proﬁle of OROS-MPH
contributes to slower absorption and brain entry, as well as sustained
dopamine receptor and transporter occupancies (Parasrampuria et al.,
2007; Spencer et al., 2006). These results suggest that OROS-MPH has a
lower abuse potential than IR-MPH. In the current study, although we
could not directly evaluate the risk for substance abuse associated with
MPH treatment in ADHD patients, we could compare activation levels
of brain regions related to monetary reward processing between
post-medication ADHD patients and healthy children and adolescents.
In a previous fMRI study, an increase in the activation of the ventral
striatum during monetary reward anticipation in cannabis users relative
to the drug-naive controls was observed (Nestor et al., 2010). Buckholtz
et al. (2010) noted that neurochemical and neurophysiological hyper-
reactivity in the dopaminergic reward system, such as nucleus
accumbens comprises a neural substrate for impulsive–antisocial behav-
ior and substance abuse in psychopathy. In the present study, we did not
observe hyper-activated brain regions (nucleus accumbens and thala-
mus) during both high and low monetary reward processing in ADHD
patients after OROS-MPH treatment in comparisonwith healthy children
and adolescents. These results suggest that OROS-MPH treatment for
3 months in ADHD children and adolescents may present a low risk for
the development of substance abuse.
In conclusion, decreased reward sensitivity, based on decreased
activation of the nucleus accumbens and thalamus during the low
monetary reward condition, and ADHD symptoms were improved by
OROS-MPH treatment for 3 months in ADHD children and adolescents.
In addition, hyper-activated brain areas of ADHD patients, relative to
the healthy children and adolescents, during monetary reward after
OROS-MPH treatment were not observed. Further study is necessary
to identify the extent of treatment effects of OROS-MPH in children
and adolescents with ADHD using placebo trials. However, the present
ﬁndings suggest that OROS-MPH treatment for a 3-month period is ef-
fective for children and adolescents with ADHD and that the current
AB
Fig. 3. Statistical parametric maps of (A) reward sensitivity (HMR minus LMR) in healthy controls (HC) and ADHD patients before (btADHD) and after treatment (atADHD) with
OROS-MPH and of (B) the effects of OROS-MPH treatment on brain activation during low monetary reward (HC minus btADHD and atADHD minus btADHD) are shown. Right
(R) and left (L) sides and y-axis (MNI coordinate) are indicated.
374 K. Mizuno et al. / NeuroImage: Clinical 2 (2013) 366–376fMRI experiments are useful for the objective non-invasive evaluation
of dopaminergic function following OROS-MPH treatment.
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Brain region
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BIS −10.5 ± 3.8 −17.7 ± 7.6 −7.4 ± 2.7
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